← Oncology Approval Tracker

FDA DECISION ·

Tecentriq Hybreza

atezolizumab + hyaluronidase-tqjs · Genentech

FDA approvalNew or expanded indicationAlveolar soft part sarcoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Expands subcutaneous use in unresectable or metastatic alveolar soft part sarcoma to pediatric patients age 12 years or older who weigh at least 40 kg.

LAMPGEN ANALYSIS

Why it matters

The subcutaneous formulation became an option for eligible adolescents with this rare sarcoma.

What research teams should watch

Confirm age and weight and coordinate specialty sarcoma assessment with route-specific administration training.

PRIMARY RECORDS

Sources